Equities Analysts Set Expectations for PTCT FY2025 Earnings

PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) - Stock analysts at Cantor Fitzgerald decreased their FY2025 earnings per share (EPS) estimates for shares of PTC Therapeutics in a report released on Monday, June 30th. Cantor Fitzgerald analyst K. Kluska now anticipates that the biopharmaceutical company will post earnings of $8.20 per share for the year, down from their previous estimate of $8.50. Cantor Fitzgerald currently has a "Overweight" rating and a $112.00 target price on the stock. The consensus estimate for PTC Therapeutics' current full-year earnings is ($4.52) per share.

PTC Therapeutics (NASDAQ:PTCT - Get Free Report) last announced its earnings results on Tuesday, May 6th. The biopharmaceutical company reported $10.04 earnings per share for the quarter, beating the consensus estimate of $0.85 by $9.19. PTC Therapeutics had a net margin of 33.56% and a negative return on equity of 78.56%. The business had revenue of $1.18 billion for the quarter, compared to the consensus estimate of $437.16 million. During the same quarter in the prior year, the firm posted ($1.20) earnings per share. The business's revenue for the quarter was down 9.6% on a year-over-year basis.

Other equities research analysts also recently issued reports about the company. Barclays reduced their price target on PTC Therapeutics from $56.00 to $42.00 and set an "equal weight" rating on the stock in a report on Thursday, May 8th. Truist Financial started coverage on PTC Therapeutics in a research note on Tuesday, June 17th. They issued a "buy" rating and a $80.00 target price on the stock. Wall Street Zen downgraded PTC Therapeutics from a "strong-buy" rating to a "buy" rating in a research report on Friday, May 16th. JPMorgan Chase & Co. cut their price target on shares of PTC Therapeutics from $75.00 to $67.00 and set an "overweight" rating on the stock in a report on Wednesday, May 7th. Finally, Wells Fargo & Company raised their price target on shares of PTC Therapeutics from $68.00 to $74.00 and gave the stock an "overweight" rating in a research note on Tuesday, May 27th. One analyst has rated the stock with a sell rating, four have issued a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $65.00.

PTC Therapeutics Stock Down 0.5%

PTC Therapeutics stock traded down $0.25 during midday trading on Tuesday, reaching $48.59. The stock had a trading volume of 1,159,528 shares, compared to its average volume of 861,660. The firm has a market cap of $3.85 billion, a price-to-earnings ratio of 7.46 and a beta of 0.51. PTC Therapeutics has a 52-week low of $29.02 and a 52-week high of $58.38. The company has a fifty day moving average of $48.25 and a 200 day moving average of $48.26.

Insider Activity

In other PTC Therapeutics news, EVP Lee Scott Golden sold 897 shares of the firm's stock in a transaction that occurred on Wednesday, April 2nd. The shares were sold at an average price of $46.95, for a total value of $42,114.15. Following the completion of the sale, the executive vice president directly owned 75,997 shares in the company, valued at $3,568,059.15. This trade represents a 1.17% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Mark Elliott Boulding sold 1,929 shares of the company's stock in a transaction on Thursday, May 15th. The stock was sold at an average price of $46.18, for a total value of $89,081.22. Following the transaction, the vice president directly owned 103,901 shares in the company, valued at approximately $4,798,148.18. The trade was a 1.82% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 6,513 shares of company stock worth $308,498. Corporate insiders own 5.50% of the company's stock.

Institutional Trading of PTC Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in PTCT. Raymond James Financial Inc. purchased a new position in PTC Therapeutics in the 4th quarter worth $2,200,000. Natixis Advisors LLC purchased a new position in PTC Therapeutics during the 4th quarter worth approximately $544,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in PTC Therapeutics by 49.2% during the 4th quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 46,894 shares of the biopharmaceutical company's stock valued at $2,117,000 after acquiring an additional 15,459 shares during the period. Proficio Capital Partners LLC purchased a new stake in shares of PTC Therapeutics in the 4th quarter valued at $758,000. Finally, Quantinno Capital Management LP acquired a new stake in shares of PTC Therapeutics in the fourth quarter worth $436,000.

About PTC Therapeutics

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.